Table 1.

Representative clinical trials of LNP-based and DC-based mRNA cancer vaccines.

Name	RNA encoding antigen	Tumour	Formulation type	Administration route	NCT number	Phase
FixVac	MAGE-A3, NY-ESO-1, tyrosinase, TPTE	Melanoma	LNP	intravenous	NCT02410733	I
mRNA-2416	OX40L	Solid Tumor Malignancies or Lymphoma	LNP	Intratumoural	NCT03323398	I/II
mRNA-2752	OX40L, IL-23, IL-36Ƴ	Solid Tumor Malignancies or Lymphoma	LNP	Intratumoural	NCT03739931	I
mRNA-4157	Personalized neoantigens	Melanoma	LNP	intramuscular	NCT03897881	II
mRNA-4650	Personalized neoantigens	Gastrointestinal cancer	LNP	intramuscular	NCT03480152	I/II
mRNA-5671/V941	KRAS antigens	Colorectal cancer, non-small-cell lung cancer, pancreatic adenocarcinoma	LNP	intramuscular	NCT03948763	I
W_ova1	Ovarian cancer antigens	Ovarian cancer	LNP	intravenous	NCT04163094	I
HARE-40	HPV oncoproteins E6 and E7	HPV oncoproteins E6 and E7	LNP	intradermal	NCT03418480	I/II
RO7198457	Personalized neoantigens	Melanoma	LNP	intravenous	NCT03815058	II
TNBC-MERIT	Personalized neoantigens	Triple-negative breast cancer	LNP	intravenous	NCT02316457	I
MEDI1191	IL-12	Solid tumours	LNP	Intratumoural	NCT03946800	I
SAR441000	IL-12sc, IL-15sushi, IFNα and GM-CSF	Solid tumours	LNP	Intratumoural	NCT03871348	I
TriMixDC-MEL	MAGE-A3, MAGE-C2, tyrosinase, gp100	Melanoma	DC-based	intravenous and intradermal	NCT01066390	I
TriMixDC-MEL	MAGE-A3, MAGE-C2, tyrosinase, gp100	Melanoma	DC-based	intravenous and intradermal	NCT01676779	II
TriMixDC-MEL	CTLA-4 inhibitor ipilimumab	Melanoma	DC-based	intravenous and intradermal	NCT01302496	II
Not available	TAA-transfected DC	melanoma	DC-based	intradermal	NCT01278940	I/II